Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20.
   PubMed Web of Science ®Google Scholar
• Lutterbach J, Guttenberger R, Pagenstecher A. Gliosarcoma: a clinical study. Radiother Oncol 2001;61:57–64.
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Dinapoli RP, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 1998;89:425–30.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.
   PubMed Web of Science ®Google Scholar
• Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8:1117–21.
   PubMed Web of Science ®Google Scholar
• Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20–37.
   PubMed Web of Science ®Google Scholar
• Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 2009;11:183–91.
   PubMed Web of Science ®Google Scholar
• Frandsen J, Orton A, Jensen R, et al. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 2018;128:1133–8.
   PubMed Web of Science ®Google Scholar
• Yi X, Cao H, Tang H, et al. Gliosarcoma: a clinical and radiological analysis of 48 cases. Eur Radiol 2018;29:429–438.
   PubMed Web of Science ®Google Scholar
• Shin JY, Yoon JK, Diaz AZ. Gliosarcoma in septuagenarians and octogenarians: what is the impact of adjuvant chemoradiation? J Clin Neurosci 2017;45:77–82.
   PubMed Web of Science ®Google Scholar
• Walker GV, Gilbert MR, Prabhu SS, et al. Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 2013;112:83–9.
   PubMed Web of Science ®Google Scholar
• Jain A, Correia J, Schweder P, et al. Analysis of outcomes of multidisciplinary management of gliosarcoma: a single-center study, 2000–2013. World Neurosurg 2017;106:30–6.
   PubMed Web of Science ®Google Scholar
• Adeberg S, Bernhardt D, Harrabi SB, et al. Radiotherapy plus concomitant temozolomide in primary gliosarcoma. J Neurooncol 2016;128:341–8.
   PubMed Web of Science ®Google Scholar
• Reis RM, Könü-Lebleblicioglu D, Lopes JM, et al. Genetic profile of gliosarcomas. Am J Pathol 2000;156:425–32.
   PubMed Web of Science ®Google Scholar
• Biernat W, Aguzzi A, Sure U, et al. Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol 1995;54:651–6.
   PubMed Web of Science ®Google Scholar
• Actor B, Cobbers JMJL, Büschges R, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosom Cancer 2002;34:416–27.
   PubMed Web of Science ®Google Scholar
• Lee D, Kang SY, Suh Y-L, et al. Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 2012;107:643–50.
   PubMed Web of Science ®Google Scholar
• Cachia D, Kamiya-Matsuoka C, Mandel JJ, et al. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol 2015;125:401–10.
   PubMed Web of Science ®Google Scholar
• Yasuda T, Nitta M, Komori T, et al. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. Neuropathology 2018;38:41–6.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Hitotsumatsu T, Sugita Y, et al. Gliosarcoma arising from oligodendroglioma (oligosarcoma): a case report with genetic analyses. Pathol Int 2018;68:567–73.
   PubMed Web of Science ®Google Scholar
• Zhang G, Huang S, Zhang J, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. J Neurooncol 2016;127:355–62.
   PubMed Web of Science ®Google Scholar
• Singh G, Mallick S, Sharma V, et al. A study of clinico-pathological parameters and O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. Neuropathology 2012;32:534–42.
   PubMed Web of Science ®Google Scholar
• Kang S-H, Park K-J, Kim C-Y, et al. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J Neurooncol 2011;101:477–86.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 2016;34:1611–9.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 2017;377:1954–63.
   PubMed Web of Science ®Google Scholar
• Srivastava H, Dewan A, Sharma S, et al. Adjuvant radiation therapy and temozolomide in gliosarcoma: is it enough? Case series of seven patients. Asian J Neurosurg 2018;13:297–301.
   PubMedGoogle Scholar